Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 10/20 | 0.39 |
| ▸ | PPARA | Q07869 | 8/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311342 | 0.84 | SRR (0.48) | SRRPPARGPPARA | |
| SCHEMBL6487486 | 0.84 | SRR (0.48) | SRRPPARGPPARA | |
| Cyclohexylamine SCHEMBL8637515 | 0.78 | SRR (0.45) | SRRPPARGPPARA | |
| SCHEMBL16861248 | 0.78 | SRR (0.47) | SRR | |
| SCHEMBL17846160 | 0.77 | MEN1 (0.41) | MEN1KMT2AKDM4C | |
| SCHEMBL6879618 | 0.75 | KDM4C (0.58) | MEN1KMT2AKDM4C | |
| SCHEMBL3506600 | 0.75 | KDM4C (0.42) | MEN1KMT2AKDM4C | |
| SCHEMBL3881607 | 0.75 | SLC6A3 (0.51) | — | |
| SCHEMBL14945228 | 0.74 | MEN1 (0.44) | MEN1KMT2AKDM4C | |
| SCHEMBL5089723 | 0.74 | MEN1 (0.46) | MEN1KMT2AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8624044-B2 | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions | ARISGEN SA (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20120301401-A1 | ORTHOESTER DERIVATIVES OF CROWN ETHERS AS CARRIERS FOR PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS | ARISGEN SA (CH) | 2012-11-29 | — | — | US | disclosed |
| EP-2332929-A1 | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions | ArisGen SA (CH) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011064300-A1 | ORTHOESTER DERIVATIVES OF CROWN ETHERS AS CARRIERS FOR PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS | ARISGEN SA (CH) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301401-A1 | ORTHOESTER DERIVATIVES OF CROWN ETHERS AS CARRIERS FOR PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS | OXER1, CBR3, CBR1 | MEN1 3657/4885KMT2A 2385/4885SRR 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.